In December 2016, Health Canada approved the purchase of a new botulism antitoxin called Botulism Antitoxin Heptavalent (BAT) from the American-based company Emergent Biosolutions, a global specialty biopharmaceutical company. The Public Health Agency of Canada has identified botulism as a likely biological terrorist threat.[1]